Durham Research Center, 8008
985880 Nebraska Medical Center
Omaha, NE 68198-5880
E-mail: Howard E. Gendelman
Keywords:HIV, neuroAIDS, long-acting antiretrovirals, nanomedicine, macrophages, neuroregeneration, Parkinson's Disease
In the news
Dr. Gendelman's biographical information
Visit Dr. Gendelman's laboratory
UNMC Today | February 1, 2017
Novel pharmaceutic action for HIV/AIDS discovered
UNMC Today | November 21, 2016
UNMC scientists honored for neurovirology impact
UNMC Today | April 12, 2016
Under the Microscope: Parkinson's Disease research
Medical News Today | December 17, 2015
New drug that protects dopamine cells raises treatment hope for Parkinson's
UNMC Today | December 16, 2015
UNMC teams on Parkinson's disease preclinical study
UNMC Today | October 28, 2015
Awards given to recognize efforts in battle against Parkinson's disease
UNMC Today | October 26, 2015
Experimental treatment regimen effective against HIV
University of Rochester public relations | October 26, 2015
Dr. Howard E. Gendelman is the Margaret R. Larson Professor of Internal Medicine and Infectious Diseases, Chairman of the Department of Pharmacology and Experimental Neuroscience, and Director of the Center for Neurodegenerative Disorders at the University of Nebraska Medical Center. Dr. Gendelman is credited in unraveling how functional alterations in brain immunity induce metabolic changes and ultimately lead to neural cell damage for a broad range of infectious, metabolic and neurodegenerative disorders. These discoveries have had broad implications in developmental therapeutics aimed at preventing, slowing or reversing neural maladies. He is also credited for the demonstration that AIDS dementia is a reversible metabolic encephalopathy; a finding realized at the University of Nebraska Medical Center. His work has led to novel immunotherapy and nanomedicine strategies for Parkinson’s and viral diseases being tested in early clinical trials as a result of intense translational investigations.
Dr. Gendelman obtained a Bachelor’s degree in Natural Sciences and Russian Studies with honors from Muhlenberg College and his M.D. from the Pennsylvania State University-Hershey Medical Center where he was the 1999 Distinguished Alumnus. He completed a residency in Internal medicine at Montefiore Hospital, Albert Einstein College of Medicine and was a Clinical and Research Fellow in Neurology and Infectious Diseases at the Johns Hopkins University Medical Center. He occupied senior faculty and research positions at the Johns Hopkins Medical Institutions, the National Institute of Allergy and Infectious Diseases, the Uniformed Services University of the Health Sciences Center, the Walter Reed Army Institute of Research, and the Henry Jackson Foundation for the Advancement in Military Medicine before joining the University of Nebraska Medical Center faculty in March of 1993. He retired from the US Army with the rank of Lieutenant Colonel. Dr. Gendelman has authored over 400 peer-reviewed publications, edited nine books and monographs, holds eight patents, is the Editor-In-Chief and Founder of the Journal of Neuroimmune Pharmacology along with service on numerous editorial boards, national and international scientific review and federal and state committees. He has been an invited lecturer to more than 200 scientific seminars and symposia and the recipient of numerous local, national and international honors. These, include, but are not limited to, the Henry L. Moses Award in Basic Science; the Carter-Wallace Fellow for Distinction in AIDS Research, the David T. Purtilo Distinguished Chair of Pathology and Microbiology, the UNMC Scientist Laureate; NU Outstanding Research and Creativity, 2013 UNMC Innovator of the Year, the 2014 Outstanding Faculty Mentor of Graduate Students and the Joseph Wybran Distinguished Scientist Awards. Dr. Gendelman was named a J. William Fulbright Research Scholar at the Weizmann Institute of Science in Israel. In 2001, he received the prestigious Jacob Javits Neuroscience Research Award from the National Institute of Neurological Disorders and Stroke and the Career Research Award in Medicine from the Department of Internal Medicine, UNMC.
He is included amongst a selective scientific group listed on highly cited.com as one of the top cited scientists in his field. Dr. Gendelman has trained more than forty scientists (students and postdoctoral fellows) who have themselves developed independent successful careers. Under his leadership, the department now holds scores of independent R01s or equivalent grants, four program project grants, and shares two program developmental awards. His leadership is credited with the growth of the Department of Pharmacology and Experimental Neuroscience at the University of Nebraska Medical Center to be amongst the top-like ranked and federally funded departments (top ten) nationwide; a particularly noted feat as its position was 89 when he assumed its leadership.
The neuroregeneration laboratory provides the student or postdoctoral fellow with broad research experiences in diagnostics, pathogenic mechanisms and therapies for neurodegenerative disorders.
The major focus for our research is on the role played by glial inflammatory activities in brain disease. The work bridges immunology, neuroscience and pharmacology and crosses disease barriers for studies of HIV-1-associated neurocognitive disorders, Parkinson’s disease (PD) and amyotrophic lateral sclerosis (ALS). The major goal is to use immune-based approaches to reverse nerve cell damage.
The laboratory initiative is divided into specific programs with cross-disciplinary support provided through experienced senior scientists. Specific expertise is available in proteomics, immunology, molecular neuroscience, infectious disease, neurophysiology and neuropathogenesis.
Research priorities in nanomedicine focuses on drug delivery to the central nervous system using "smart" drugs that are packaged into immunocytes and use “Trojan horse” cell-based mechanisms to by-pass the blood-brain barrier and enter diseased brain areas. These are intertwined with studies of disease pathogenesis focused on studies of the biophysical and effector cell properties of blood-borne macrophages that modulate leukocyte entry and glial immunity.
Our nanomedicine program provides laboratory experiences in nanoformulations and physical chemistry linked to characterization of nanoparticles as well as animal studies of disease pathobiology using "state of the art" drug delivery systems. Coordinate drug testing (anti-inflammatory, neuroprotective and anti-retroviral) in HIV-1 encephalitis (HIVE) and PD are pursued with adjunctive drugs distinct or part of the nanomedicine efforts.
This program is part of multiple National Institutes of Health grant efforts that involve scientists at the University of Nebraska Medical Center (College of Medicine and College of Pharmacy), the University of Rochester, and Columbia University College of Physicians and Surgeons. The focus is to perform translational research that would move quickly from animals to humans and currently involves human phase I testings.
Our neuroimmunologic and vaccine approaches have shown tremendous success in recent years for their abilities to induce protective immunity and protect against ongoing neurodegeneration. These are being pursued in animal models of HIVE, PD and ALS.
Our proteomic and metabolomic studies involve basic cell biology and molecular studies of virus-cell interactions in the setting of abused drugs.
All together this is a rich offering in scientific disciplines and relevant human disease models that can readily translate from the laboratory bench to the clinic.
- Gendelman HE, Gelbard HA. (2014) Adjunctive and long-acting nanoformulated antiretroviral therapies for HIV-associated neurocognitive disorders. Cur Opin HIV AIDS 9(6):585-590. PMID 25226025
- Edagwa BJ, Zhou T, McMillan JM, Liu XM, Gendelman HE. (2014) Development of HIV Reservoir Targeted Long Acting Nanoformulated Antiretroviral Therapies. Curr Med Chem. 21(36):4186-98 PMID 25174930
- Edagwa BJ, Guo D, Puligujja P, Chen H, McMillan J, Liu X, Gendelman HE, Narayanasamy P. (2014) Long-acting antituberculous therapeutic nanoparticles target macrophage endosomes. FASEB J [Epub ahead of print]. PMID 25122556
- Heinrichs-Graham E, Kurz MJ, Becker KM, Santamaria PM, Gendelman HE, Wilson TW. (2014) Hyper-synchrony despite pathologically-reduced beta oscillations in patients with Parkinson's disease: A pharmaco-magnetoencephalography study. J Neurophysiol [Epub ahead of print] PMID 25008416
- Guo D, Zhang G, Wysocki TA, Wysocki BJ, Gelbard HA, Liu XM, McMillan JM, Gendelman HE. (2014) Endosomal trafficking of nanoformulated antiretroviral therapy facilitates drug particle carriage and HIV clearance. J Virol 88(17): 9504-13. PMID 24920821
- Singh D, McMillan JM, Kabanov AV, Sokolsky-Papkov M, Gendelman HE. (2014) Bench-to-bedside translation of magnetic nanoparticles. Nanomedicine (Lond) 9(4): 501-16. PMID 24910878
- Nell A, Swindells S, Bronich T, Gendelman HE. (2014) Interview: Nanomedicine and the fight against HIV/AIDS. Nanomedicine (Lond) 9(2): 1-14.PMID 24552561
- Gendelman HE, Mosley RL, Boska MD, McMillan J. (2014) The promise of nanoneuromedicine. Nanomedicine (Lond) 9(2): 171-176. PMID: 24552556
- Martinez-Skinner AL, Veerubhotla RS, Liu H, Xiong H, Yu F, McMillan JM, Gendelman HE. (2013) Functional proteome of macrophage carried nanoformulated antiretroviral therapy demonstrates enhanced particle carrying capacity. J Proteome Res. 12(5):2282-94. PMID 23544708
- Nowacek A, Kadiu I, McMillan J, Gendelman HE. (2013) Immunoisolation of nanoparticles containing endocytic vesicles for drug quantitation. Methods Mol Biol. 991:41-6. PMID 23546657